{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:26:18Z","timestamp":1769016378642,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives de P\u00e9diatrie"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.arcped.2025.01.008","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:06:58Z","timestamp":1744128418000},"page":"231-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events associated with intravenous immunoglobulin infusions in pediatric patients with primary immunodeficiency: A 10-year single-center study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7489","authenticated-orcid":false,"given":"Murat","family":"\u00d6zer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seher","family":"Tekeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sel\u00e7uk","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u0131dvan","family":"Selen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caner","family":"Aytekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcped.2025.01.008_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166821","article-title":"Antibody diversity in IVIG: therapeutic opportunities for novel immunotherapeutic drugs","volume":"14","author":"Von Gunten","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0002","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.arcped.2025.01.008_bib0003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.24953\/turkjped.2020.03.004","article-title":"Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience","volume":"62","author":"Nain","year":"2020","journal-title":"Turk J Pediatrics"},{"key":"10.1016\/j.arcped.2025.01.008_bib0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arcped.2025.01.008_bib0005","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0006","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0007","unstructured":"European Society for Immunodeficiencies (ESID). [Internet] Diagnostic criteria for PID. Available at: https:\/\/esid.org\/Working-Parties\/Registry-Working-Party (Accessed on 7th September 2022)."},{"key":"10.1016\/j.arcped.2025.01.008_bib0008","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 update of IUIS phenotypical classification for human inborn errors of immunity","volume":"42","author":"Bousfiha","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.arcped.2025.01.008_bib0011","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5415\/apallergy.2013.3.4.249","article-title":"Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study","volume":"3","author":"Palabrica","year":"2013","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.arcped.2025.01.008_bib0012","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","article-title":"Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients","volume":"40","author":"Schroeder","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.arcped.2025.01.008_bib0013","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.aller.2020.05.008","article-title":"Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement","volume":"48","author":"Ibis","year":"2020","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.arcped.2025.01.008_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.740517","article-title":"A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion","volume":"12","author":"Kato","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0015","first-page":"11","article-title":"Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience","volume":"49","author":"Kaba","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0016","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","volume":"23","author":"Bichuetti-Silva","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0017","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1440-1754.1988.tb00319.x","article-title":"Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial","volume":"24","author":"Roberton","year":"1988","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.arcped.2025.01.008_bib0018","first-page":"713","article-title":"Immunoglobulin replacement therapy for primary immunodeficiency","volume":"35","author":"Sriaroon","year":"2015","journal-title":"Immunology and Allergy Clinics"},{"key":"10.1016\/j.arcped.2025.01.008_bib0019","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content","volume":"121","author":"Manlhiot","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.arcped.2025.01.008_bib0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1537-2995.1997.37497265353.x","article-title":"Clinical impact of anti-D in intravenous immunoglobulin","volume":"37","author":"Friedman","year":"1997","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.arcped.2025.01.008_bib0021","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1423-0410.2003.00336.x","article-title":"Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity","volume":"85","author":"Thorpe","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.arcped.2025.01.008_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227796","article-title":"Predictive factors of first dosage intravenous immunoglobulin-related adverse effects in children","volume":"15","author":"Kubota","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.arcped.2025.01.008_bib0023","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","article-title":"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk","volume":"38","author":"Dantal","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0024","first-page":"139","article-title":"7 Adverse reactions of prophylactic intravenous immunoglobulin; A 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Khavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1081-1206(10)61711-5","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency","volume":"92","author":"Aghamohammadi","year":"2004","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaci.2011.01.061","article-title":"Association of anti-IgA antibodies with adverse reactions to \u03b3-globulin infusion","volume":"128","author":"Rachid","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000056085","article-title":"Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases","volume":"62","author":"Sherer","year":"2001","journal-title":"Pharmacology"},{"key":"10.1016\/j.arcped.2025.01.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108826","article-title":"Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin","volume":"230","author":"Esmaeilzadeh","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.arcped.2025.01.008_bib0029","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-012-9656-5","article-title":"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency","volume":"32","author":"Wasserman","year":"2012","journal-title":"J Clin Immunol"}],"container-title":["Archives de P\u00e9diatrie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X25000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X25000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:10:02Z","timestamp":1768961402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929693X25000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0929693X25000557"],"URL":"https:\/\/doi.org\/10.1016\/j.arcped.2025.01.008","relation":{},"ISSN":["0929-693X"],"issn-type":[{"value":"0929-693X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events associated with intravenous immunoglobulin infusions in pediatric patients with primary immunodeficiency: A 10-year single-center study","name":"articletitle","label":"Article Title"},{"value":"Archives de P\u00e9diatrie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcped.2025.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de p\u00e9diatrie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}